Intercept Pharma

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Intercept Pharma reports robust earnings, eyes growth amid competitive challenges

Intercept Pharma's Q4 2022 earnings call highlighted strong financial performance, strategic advancements, and a focus on innovation and market expansion.
The company's achievements in sales growth, patent protection, and financial stability position it well for future growth and leadership in the PBC and NASH markets.
Challenges in competitive dynamics and regulatory landscape require proactive strategies, while opportunities in new programs and market developments offer avenues for continued success.
Overall, Intercept Pharma's performance underscores a resilient and forward-thinking approach to navigating the complexities of the pharmaceutical industry and driving sustainable growth.

Intercept Pharma reports growth in sales and navigates NASH landscape

Intercept Pharma's Q1 2023 performance saw growth in net sales and strong sales performance of OCALIVA.
The company's focus on F3-like NASH patients and competitive positioning of OCA are key strengths.
Challenges include pricing strategy discussions and questions on combination approaches.
Opportunities lie in addressing AdCom discussions, expanding prescriber base, and preventing cirrhosis progression.

Intercept Pharma reports strong Q2 earnings, eyes FDA relations

Intercept Pharma's strong performance in Q2 2023 shows progress towards profitability by 2024. The company is addressing challenges in FDA relations and study enrollments while leveraging market opportunities for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intercept Pharmaceuticals is a biopharmaceutical company, that engages in discovering and developing small molecule drugs and therapeutics for the treatment of chronic fibrotic and metabolic diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic autoimmune liver diseases. The company's drug development programs also focus on modulating bile acid receptors, and amelioration of metabolic and hepatic functions in chronic liver diseases.

Worldwide Ocaliva net sales of $77.2 million in the second quarter 2020, representing 17% growth over the prior year quarter 

Intercept Pharmaceuticals Reports Second Quarter 2020 Financial Results, Announces Updates to Financial Guidance and Provides Business Update

Amicus Therapeutics

Halozyme Therapeutics

Novavax

Reata Pharmaceuticals

Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.

Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More

Intercept (ICPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Intercept (ICPT)

Arcturus Therapeutics

AvroBio Inc

89bio Inc

Fulcrum Therapeutics Inc

Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.

5 Biotech Stocks Set to Outpace Q2 Earnings Estimates

NEW YORK, Aug.  03, 2020  (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2020 financial results prior to market open on Monday, August 10, 2020. The announcement will be followed by a conference call and audio webcast hosted by Intercept management at 8:30 a.m. ET to discuss the results.

Intercept to Announce Second Quarter 2020 Financial Results on August 10, 2020

Intercept (ICPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intercept Pharmaceuticals (ICPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

An approval pathway for OCA in treating NASH still exists. But it appears to be a steeper path.

Should You Throw in the Towel on Intercept Pharmaceuticals After Its Big Setback?

Intercept (ICPT) down on receipt of CRL for its NDA seeking approval of OCA for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).

Intercept Slumps as the FDA Issues CRL to NASH Candidate

The Food and Drug Administration rejected Intercept Pharmaceuticals' therapy for an obesity-linked liver disease — sending ICPT stock crashing on Monday. Shares hit a seven-year low.

Biotech Crashes To 7-Year Low On Surprise FDA Rejection In Liver Disease

LOS ANGELES--(BUSINESS WIRE)---- $ICPT #classaction--The Law Offices of Frank R. Cruz announces an investigation on behalf of Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT) investors concerning the Company and its officers’ possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On June 29, 2020, Intercept disclosed receipt of a complete response letter ("CRL") from the U.S. Food and Drug Administration ("FDA") regarding t

The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Intercept Pharmaceuticals, Inc.

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) shares were retreating sharply Monday on the back of an FDA rejection of its lead non-alcoholic steatohepatitis drug.

Why Shares Of NASH Biotech Intercept Pharma Are Slumping

Shares of Intercept Pharmaceuticals, Inc (Nasdaq: ICPT) plunged over 40% after the U.S. U.S. Food and Drug Administration (FDA) declined to approve the firm’s therapy for liver disease.

Here’s why Intercept stock price collapsed 40% today

The pharmaceutical company's attempt to get obeticholic acid approved for the lucrative non-alcoholic steatohepatitis market has hit a (perhaps temporary) roadblock.

FDA Tells Intercept Pharmaceuticals No on Its NASH Drug Candidate -- for Now

Shares are taking a step back after the FDA rejected the company's NASH candidate.

Why Intercept Pharmaceuticals Stock Is Crashing Today

Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) says it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for obeticholic acid (OCA) its treatment of fibrosis due to nonalcoholoic steatohepatitis (NASH). The stock was crushed early on Monday.

What This FDA Update Means for Intercept Pharma

Intercept Pharmaceuticals Inc. shares ICPT, -2.65% tumbled more than 30% in premarket trade Monday, after the company said it has received a U.S.

Intercept Pharmaceuticals receives FDA Complete Response Letter for treatment for fibrosis due to NASH

Conference call scheduled for 8:30 a.m. ET today Conference call scheduled for 8:30 a.m. ET today

Intercept Receives Complete Response Letter from FDA for Obeticholic Acid for the Treatment of Fibrosis Due to NASH

Madrigal Pharmaceuticals

These two companies are going after the same target, but which one should you bet on today?

Better Buy: Intercept Pharmaceuticals vs. Madrigal Pharmaceuticals

Here's why this leader in treating progressive non-viral liver disease is, in fact, a solid buy.

Is Intercept Pharmaceuticals Stock a Buy?

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock?

Why Is Intercept (ICPT) Down 9.4% Since Last Earnings Report?

Intercept Pharmaceuticals: Undervalued Ahead Of An Eventful Period

This drug developer has first-mover advantage in an untapped $35 billion indication.

Here's My Single Best Investment Idea for June

The FDA defers advisory committee meeting date pertaining to Intercept's (ICPT) NDA for obeticholic acid to treat liver fibrosis due to nonalcoholic steatohepatitis.

Intercept Down on Postponement of AdCom Meet for NASH Drug

Investors are feeling more uncertainty about whether obeticholic acid will be approved as a treatment for liver fibrosis due to nonalcoholic steatohepatitis.

Intercept Pharmaceuticals Shares Fall 13% After FDA Delays an Advisory Committee Meeting

The company received some bad news from the FDA.

News for Intercept Pharma Stock (ICPT)